Search results for "IGF"

showing 10 items of 68 documents

Contribución de IGF-I en la hiperplasia mamaria promovida por AIB1

2015

El oncogén AIB1 (Amplified in Breast Cancer 1) es un coactivador de la transcripción de genes implicados en la respuesta fisiológica a hormonas y factores de crecimiento. La sobreexpresión de AIB1 es una característica frecuente en muchos tipos de cáncer, incluyendo el de mama. Diferentes estudios con líneas celulares y modelos animales han demostrado que AIB1 interacciona con la ruta de señalización de IGF-I/PI3K/AKT a diferentes niveles moleculares. Por otra parte, la señalización mediada por IGF-I a través de su receptor IGF-IR juega un papel muy importante en el desarrollo de la glándula mamaria y en los procesos patológicos que ocurren en este tejido. Debido a esto, existen múltiples i…

AIB1OncogénUNESCO::CIENCIAS MÉDICASHiperplasia mamaria:CIENCIAS MÉDICAS [UNESCO]IGF-I
researchProduct

SHIP2: A “NEW” Insulin Pathway Target for Aging Research

2014

Strong evidence suggests that systemic inflammation and central adiposity contribute to and perpetuate metabolic syndrome. All of these alterations predispose individuals to type 2 diabetes mellitus (T2DM), cardiovascular disease, as well as Alzheimer's disease (AD), all characterized by chronic inflammatory status. On the other hand, extensive abnormalities in insulin and insulin-like growth factor I (IGF-I) and IGF-II signaling mechanisms in brains with AD have been demonstrated, suggesting that AD could be a third form of diabetes. The Src homology domain-containing inositol 5-phosphatase 2 (SHIP2) has an important role in the insulin pathway because its over-expression causes impairment…

AdultAgingmedicine.medical_specialtymedicine.medical_treatmentDiseaseBiologySystemic inflammationPolymorphism Single Nucleotidepolymorphismchemistry.chemical_compounddomain-containing inositol 5-phosphatase 2 (SHIP2) insulin-like growth factor I (IGF-I) type 2 diabetes mellitus (T2DM)INFLAMMATIONGene FrequencyAlzheimer DiseaseDiabetes mellitusInternal medicinemedicineHumansInsulinSettore MED/05 - Patologia ClinicaSNPInositolAgedSettore MED/04 - Patologia GeneraleALZHEIMER’S DISEASEResearchInsulinInositol Polyphosphate 5-PhosphatasesNEURODEGENERATIONType 2 Diabetes Mellitusmedicine.diseasePhosphoric Monoester HydrolasesEndocrinologyDiabetes Mellitus Type 2chemistryImmunologySettore MED/26 - NeurologiaGeriatrics and Gerontologymedicine.symptomMetabolic syndromeSignal TransductionRejuvenation Research
researchProduct

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical…

2014

Abstract Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10–40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. Results: Preclinical studies demonstrated enhanced pathway inhibition with ridaforolimus and dalotuzumab. With 87 patients treated in the phase I study, main dose-limiting toxicities (DLT) of the combination were p…

AdultCancer ResearchPhases of clinical researchBreast NeoplasmsPharmacologyAntibodies Monoclonal HumanizedArticleReceptor IGF Type 1Ridaforolimuschemistry.chemical_compoundBreast cancerIn vivoAntineoplastic Combined Chemotherapy ProtocolsMedicineAnimalsHumansPI3K/AKT/mTOR pathwayInsulin-like growth factor 1 receptorAgedSirolimusDalotuzumabbusiness.industryTOR Serine-Threonine KinasesAntibodies MonoclonalReceptors SomatomedinMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysOncologychemistryMonoclonalbusinessSignal TransductionClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis

2022

The association between IGF-1 levels and mortality in humans is complex with low levels being associated with both low and high mortality. The present meta-analysis investigates this complex relationship between IGF-1 and all-cause mortality in prospective cohort studies. A systematic literature search was conducted in PubMed/MEDLINE, Scopus, and Cochrane Library up to September 2019. Published studies were eligible for the meta-analysis if they had a prospective cohort design, a hazard ratio (HR) and 95% confidence interval (CI) for two or more categories of IGF-1 and were conducted among adults. A random-effects model with a restricted maximum likelihood heterogeneity variance estimator w…

AdultCohort StudiesAgingIGF-1HumansCell BiologyProspective StudiesInsulin-Like Growth Factor Imortalityprotein intakeProportional Hazards Models
researchProduct

IGF-I, IgA, and IgG responses to bovine colostrum supplementation during training.

2002

This study examined the effect of bovine colostrum (Dynamic colostrum) supplementation on blood and saliva variables ( study 1) and the absorption of orally administered human recombinant insulin-like growth factor (IGF)-I (rhIGF-I) labeled with 123I (123I-rhIGF-I) ( study 2). In study 1, adult male and female athletes were randomly assigned in a double-blind fashion to either an experimental (Dynamic; n = 19) or a control (Placebo; n = 11) group. The former consumed daily 20 g of Dynamic supplement, and the latter 20 g of maltodextrin during a 2-wk training period. After bovine colostrum supplementation, significant increases were noticed in serum IGF-I ( P < 0.01) and saliva IgA ( P &…

AdultElectrophoresisMaleSalivamedicine.medical_specialtyPhysiologyCausticsAnimal originlaw.inventionReceptor IGF Type 1Iodine RadioisotopesDouble-Blind MethodlawPhysiology (medical)Internal medicinemedicineAnimalsHumansInsulin-Like Growth Factor ITrichloroacetic AcidSalivabusiness.industryColostrumImmunoglobulin AEndocrinologyNutrition AssessmentPhysical performancePhysical FitnessImmunoglobulin GDietary SupplementsRecombinant DNAColostrumCattleFemalebusinessJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial …

2019

Hepatocellular carcinoma (HCC) is one of the most common human malignancies, the incidence of which is growing worldwide. The prognosis of HCC is very poor and it is often accompanied by a high rate of recurrence. Conventional chemotherapeutic approaches are largely inefficient. In order to develop novel effective methods for the early detection and prognosis of HCC, novel markers and therapeutic targets are urgently required. The present study focused on the effects of the expression of the tumor suppressor gene insulin‑like growth factor‑2 receptor (IGF2R) on patient survival and tumor recurrence in patients with HCC; this study paid specific attention to the influence of transarterial ch…

AdultLiver CirrhosisMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisTumor suppressor geneKaplan-Meier EstimatePolymorphism Single NucleotideDisease-Free SurvivalReceptor IGF Type 203 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaHumansGenetic Predisposition to DiseaseChemoembolization TherapeuticAgedAged 80 and overOncogenebusiness.industryLiver NeoplasmsCase-control studyCancerGeneral MedicineMiddle AgedPrognosismedicine.diseaseMolecular medicinedigestive system diseases030104 developmental biologyOncologyCase-Control Studies030220 oncology & carcinogenesisHepatocellular carcinomaFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesOncology Reports
researchProduct

Growth hormone replacement in adults:Real-world data from two large studies in US and Europe

2020

Objective: This report describes the effectiveness and safety of growth hormone replacement in 3180 adult patients with growth hormone deficiency followed-up for 0.0–12.2 years in two completed, complementary, non-interventional, multicentre studies, NordiNet® International Outcome Study (IOS) (NCT00960128) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program (NCT01009905). Design: In both studies, Norditropin® (somatropin; Novo Nordisk A/S, Denmark) was administered at the discretion of the treating physician and according to routine practice. We present data on baseline characteristics, growth hormone dose, safety data and change from baseline in waist circumferenc…

AdultMale0301 basic medicineIGF-I SDSPediatricsmedicine.medical_specialtyWaistHormone Replacement TherapyEndocrinology Diabetes and MetabolismANSWER Program030209 endocrinology & metabolismEffectivenessGrowth hormoneNordiNet® International Outcome Study (IOS)Body compositionHypopituitarismBody Mass IndexGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyElectric ImpedancemedicineHumansGrowth hormone replacementAgedAdult patientsHuman Growth Hormonebusiness.industryMiddle Agedmedicine.diseaseRecombinant ProteinsUnited StatesReal-world dataEuropeClinical Practice030104 developmental biologyGrowth hormone deficiency in adultsBaseline characteristicsBody CompositionFemaleWaist CircumferenceSafetybusinessReal world dataBody mass index
researchProduct

Microdialysis-Assessed Exercised Muscle Reveals Localized and Differential IGFBP Responses to Unilateral Stretch Shortening Cycle Exercise

2020

Microdialysis allows for a preview into local muscle metabolism and can provide physiological insight that blood measurements cannot. Purpose: To examine the potential differential IGF-I system regulation in interstitial fluid during unilateral stretch shortening cycle exercise. Methods: 10 men (26 ± 7 year) performed unilateral jumping [stretch shortening cycle (SSC) exercise at 50% of optimal jump height] until volitional fatigue on a sled apparatus. Biological sampling took place using a catheter inserted into an antecubital vein (serum), and 100 kDa microdialysis probes inserted into the thigh muscle of each exercise/control leg (dialysate). Serum was drawn before (Pre; −3 h) and after …

AdultMale0301 basic medicinemedicine.medical_specialtyMicrodialysismicrodialysismuscleinterstitial fluidAntecubital veinEndocrinology Diabetes and Metabolismlihakset030209 endocrinology & metabolismmedicine.disease_causelcsh:Diseases of the endocrine glands. Clinical endocrinologyStretch shortening cycleYoung Adult03 medical and health sciencesEndocrinology0302 clinical medicineJumpingInterstitial fluidMuscle Stretching ExercisesInternal medicinemedicineHumansInsulin-Like Growth Factor IMuscle SkeletallihassolutOriginal Researchlcsh:RC648-665business.industryendokrinologiaRepeated measures designDifferential regulationIGF-IInsulin-Like Growth Factor Binding Proteins030104 developmental biologyEndocrinologyStretch-Shortening Cycle Exercisevoimaharjoittelustretch shortening cycle exercisebinding proteinsbusinessFrontiers in Endocrinology
researchProduct

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in p…

2011

Abstract Purpose: Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody that binds to IGF-1R preventing receptor activation. This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose. Experimental Design: Patients with tumors expressing IGF-1R protein were allocated to dose-escalating cohorts of three or more patients each and received intravenous dalotuzumab weekly, every 2 or 3 weeks. Plasma was collected for PK analysis…

AdultMaleCancer ResearchMaximum Tolerated Dosemedicine.medical_treatmentAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedDrug Administration ScheduleReceptor IGF Type 1Insulin-like growth factorPharmacokineticsNeoplasmsmedicineHumansAgedAged 80 and overDose-Response Relationship DrugDalotuzumabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseOncologyTolerabilityPharmacodynamicsMonoclonalToxicityFemalebusinessClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct